Shuttle Pharmaceuticals Holdings Inc
For the period ended Dec 31, 2023. Filed Mar 21, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 21, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Company has duly caused this Annual Report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Shuttle Pharmaceuticals Holdings, Inc. | ||
| By: | /s/ Anatoly Dritschilo, M.D. | |
| Anatoly Dritschilo, M.D. | ||
| Chairman of the board of directors, | ||
| Chief Executive Officer and President | ||
| Date: March 21, 2024 | Principal Executive Officer | |
|---|---|---|
Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ Anatoly Dritschilo | Chairman of the board of directors, | |
| Anatoly Dritschilo | Chief Executive Officer | March 21, 2024 |
| (principal executive officer) | ||
| /s/ Michael Vander Hoek | Chief Financial Officer | |
| Michael Vander Hoek | (principal financial and accounting officer) | March 21, 2024 |
| /s/ Chris H. Senanayake | Director | |
| Chris H. Senanayake | March 21, 2024 | |
| /s/ Steven Richards | Director | |
| Steven Richards | March 21, 2024 | |
| /s/ Joshua Schafer | Director | |
| Joshua Schafer | March 21, 2024 | |
| /s/ Milton Brown | Director | |
| Milton Brown | March 21, 2024 | |
| /s/ Bette Jacobs | Director | |
| Bette Jacobs | March 21, 2024 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.